Swedbank AB Buys 71,200 Shares of Vera Therapeutics, Inc. $VERA

Swedbank AB raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 142.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 121,200 shares of the company’s stock after purchasing an additional 71,200 shares during the period. Swedbank AB’s holdings in Vera Therapeutics were worth $6,138,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. GAMMA Investing LLC lifted its position in shares of Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares in the last quarter. Invesco Ltd. lifted its position in shares of Vera Therapeutics by 2.0% in the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after acquiring an additional 550 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock valued at $157,000 after acquiring an additional 639 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Vera Therapeutics by 2.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,721 shares of the company’s stock valued at $744,000 after acquiring an additional 816 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Vera Therapeutics by 1.7% in the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after acquiring an additional 825 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Price Performance

NASDAQ:VERA opened at $34.34 on Wednesday. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $2.46 billion, a P/E ratio of -6.20 and a beta of 0.96. Vera Therapeutics, Inc. has a 12 month low of $18.76 and a 12 month high of $56.05. The business’s 50-day moving average is $38.76 and its 200 day moving average is $41.02.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the prior year, the firm posted ($0.81) earnings per share. On average, equities research analysts forecast that Vera Therapeutics, Inc. will post -6.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VERA has been the topic of several research analyst reports. HC Wainwright boosted their price objective on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research report on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Finally, Evercore set a $91.00 price objective on Vera Therapeutics in a research report on Friday, May 15th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $79.00.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total value of $679,690.00. Following the sale, the chief executive officer directly owned 216,744 shares in the company, valued at approximately $7,963,174.56. The trade was a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.